In April 2004, NicOx signed an agreement with Grupo Ferrer for the research, development and marketing of novel nitric oxide-donating anti-inflammatory drugs for the treatment of dermatological diseases.
In May 2006 NCX 1047 was selected as the development candidate in their dermatology collaboration. This selection marked the successful completion of the partners’ research program, announced in September 2005, to identify a novel nitric oxide-donating anti-inflammatory with the potential for an improved risk-benefit ratio in humans.
Under the terms of the agreement NicOx is responsible for the initial synthesis of the new compounds, while Ferrer will be responsible for and fund all further development activities through to registration, under the oversight of a joint development committee. Ferrer has marketing rights for the European Union (including EFTA), Latin America, French-speaking Africa (including Morocco and Algeria) and Egypt and an option on U.S. rights, which it may exercise following the commencement of phase 2 studies. NicOx retains all rights for Asia and has the right to co-market products directly in the European Union and EFTA. NicOx will receive undisclosed development milestones and commercial success fees, plus royalties on the sales of any products resulting from the agreement.
